Marc Barry, M.D.

photo of marc barry

Associate Professor



  • Urologic Pathology
  • Medical Renal Pathology

Education and Certification Information

Brigham and Women's Hospital (Jun 2007)
Urologic Pathology

Brigham and Womens Hospital/Massachusetts Institute of Technology (Jul 2004)
Research Fellow

Brigham and Womens Hospital (Jun 2003)
Medical Renal Pathology

Brigham and Womens Hospital (Jul 2000)
Anatomic Pathology

University College Dublin (Jun 1997)

Mater Misericordiae Hospital (Jun 1996)
Medicine and Surgery

Medical School:
University College Dublin (UCD: M.D. 1995; M.Med.Sci. 1996)

Board Certifications:
Am Bd Pathology (Sub: Anatomic) : (Jul 2005)

Pathology, Anatomical
Surgical Pathology, Urologic Pathology, Nephropathology

Selected Publications:

  1. Ross RW, Galsky MD, Febbo P, Barry M, Richie JP, Xie W, Fennessy FM, Bhatt RS, Hayes J, Choueiri TK, Tempany CM, Kantoff PW, Taplin ME, Oh WK: Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: A Prostate Cancer Clinical Trials Consortium trial. Cancer. 2012; Jan 26 (epub ahead of print).

  2. Barry M, Dhillon P, Stampfer MJ, Perner S, Ma J, Giovannucci E, Kurth T, Mucci LA, Rubin MA: -Methylacyl-CoA racemase expression and lethal prostate cancer in the Physicians’ Health Study and Health Professionals Follow-up Study. Prostate. 2012 72(3):301-6.

  3. Singh P, Barry M, Tzamaloukas A: Goodpasture’s disease complicating human immunodeficiency virus infection. Clinical Nephrology 2011; 76(1): 74-7.

  4. Xu L, Begum S, Barry M, Crowley D, Yang L, Bronson RT, Hynes RO: GPR56 plays varying roles in endogenous cancer progression. Clin Exp Metastasis 2010(4); 27:241-9.

  5. Kempiah P, Danielson LA, Barry M, Kisiel W: Comparative effects of Aprotinin and human recombinant R24K KD1 on temporal renal function in Long-Evans rats. J. Pharmacology and Experimental Therapeutics. 2009; 331:1-6.

  6. Dhillon PK, Barry M, Stampfer MJ, Perner S, Fiorentino M, Fornari A, Ma J, Fleet J, Kurth T, Rubin MA, Mucci LA: Aberrant Cytoplasmic Expression of p63 and Prostate Cancer Mortality. Cancer Epidemiol Biomarkers Prev. 2009 Feb; 18(2): 595-600.

  7. Majumder P, Majumder PK, Grisanzio C, O'Connell F, Barry M, Brito JM, Xu Q, Guney I, Berger R, Herman P, Bikoff R, Fedele G, Baek WK, Wang S, Ellwood-Yen K, Wu H, Sawyers CL, Signoretti S, Hahn WC, Loda M, Sellers WR: A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell, 2008, Aug 12; 14(2): 146-55.

  8. McCarty J, Barry M, Lacy-Hulbert A, Bronson RT, Crowley D, Savill J, Hynes RO: Genetic ablation of alphaV integrins in the developing eyelid leads to Squamous Carcinoma: A potential function for alphaV integrin as a tumor suppressor. American J Pathol 2008, Jun, 172(6):1740-7.

  9. Barry M, Perner SV, Johnson L, Rubin MA: Heterogeneity for TMPRSS-ERG gene fusion in mulifocal prostate cancer. Urology 2007, 70(4): 630-3.

  10. Lacy-Hulbert A, Smith AM, Tissire H, Barry M, Crowley D, Bronson RT, Roes JT, Savill JS, Hynes RO: Ulcerative Colitis and autoimmunity induced by loss of myeloid alphav integrins. Proc. Natl. Acad. Sci. USA 2007, Oct 2; 104(40): 15823-8.

Search PubMed:

Marc Barry on PubMed